Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Diseases | 2 | 2020 | 124 | 1.130 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2020 | 83 | 0.670 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2020 | 118 | 0.590 |
Why?
|
| Imipramine | 1 | 2017 | 18 | 0.590 |
Why?
|
| Hyperpigmentation | 1 | 2017 | 13 | 0.580 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2017 | 26 | 0.580 |
Why?
|
| Ear Diseases | 1 | 2016 | 18 | 0.540 |
Why?
|
| Foreign-Body Reaction | 1 | 2016 | 15 | 0.540 |
Why?
|
| Keratin-1 | 1 | 2016 | 1 | 0.530 |
Why?
|
| Skin Neoplasms | 4 | 2019 | 796 | 0.530 |
Why?
|
| Hyperkeratosis, Epidermolytic | 1 | 2016 | 3 | 0.530 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2016 | 4 | 0.530 |
Why?
|
| Purpura Fulminans | 1 | 2015 | 6 | 0.520 |
Why?
|
| Angiokeratoma | 1 | 2015 | 1 | 0.510 |
Why?
|
| Pseudolymphoma | 1 | 2015 | 4 | 0.510 |
Why?
|
| Nail Diseases | 1 | 2015 | 14 | 0.500 |
Why?
|
| Pemphigus | 1 | 2014 | 5 | 0.490 |
Why?
|
| Photosensitivity Disorders | 1 | 2014 | 10 | 0.470 |
Why?
|
| Drug Eruptions | 1 | 2014 | 33 | 0.460 |
Why?
|
| Fluorouracil | 1 | 2014 | 128 | 0.460 |
Why?
|
| Deoxycytidine | 1 | 2014 | 76 | 0.460 |
Why?
|
| West Nile virus | 1 | 2015 | 117 | 0.460 |
Why?
|
| Immunoglobulin A | 1 | 2014 | 197 | 0.450 |
Why?
|
| Depressive Disorder | 1 | 2017 | 449 | 0.450 |
Why?
|
| West Nile Fever | 1 | 2015 | 139 | 0.440 |
Why?
|
| Gout | 1 | 2016 | 146 | 0.440 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 178 | 0.420 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 325 | 0.410 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2020 | 71 | 0.390 |
Why?
|
| Sporotrichosis | 1 | 2011 | 1 | 0.380 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 769 | 0.380 |
Why?
|
| Mutation | 2 | 2020 | 5772 | 0.270 |
Why?
|
| Face | 3 | 2019 | 180 | 0.250 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1877 | 0.240 |
Why?
|
| Dermatology | 1 | 2024 | 34 | 0.230 |
Why?
|
| Delphi Technique | 1 | 2024 | 202 | 0.210 |
Why?
|
| Consensus | 1 | 2024 | 606 | 0.190 |
Why?
|
| Aged | 7 | 2020 | 19086 | 0.180 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 14 | 0.180 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2020 | 31 | 0.180 |
Why?
|
| Plasma Cells | 1 | 2020 | 54 | 0.170 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2020 | 15 | 0.170 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2020 | 61 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2020 | 38 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 99 | 0.170 |
Why?
|
| Eyelid Neoplasms | 1 | 2020 | 43 | 0.170 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 210 | 0.170 |
Why?
|
| Rituximab | 1 | 2020 | 155 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 100 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2016 | 651 | 0.160 |
Why?
|
| Curriculum | 1 | 2024 | 719 | 0.160 |
Why?
|
| Biopsy, Needle | 2 | 2020 | 229 | 0.160 |
Why?
|
| Lymphocytes | 1 | 2020 | 402 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 324 | 0.150 |
Why?
|
| Humans | 14 | 2024 | 123072 | 0.150 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 1687 | 0.150 |
Why?
|
| Rare Diseases | 2 | 2020 | 186 | 0.140 |
Why?
|
| Cataract | 1 | 2020 | 219 | 0.140 |
Why?
|
| Female | 9 | 2020 | 65534 | 0.140 |
Why?
|
| Ear Neoplasms | 1 | 2016 | 12 | 0.140 |
Why?
|
| Neck | 1 | 2017 | 138 | 0.130 |
Why?
|
| Gangrene | 1 | 2015 | 26 | 0.130 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2015 | 67 | 0.130 |
Why?
|
| Fingers | 1 | 2015 | 65 | 0.120 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2014 | 12 | 0.120 |
Why?
|
| Capecitabine | 1 | 2014 | 16 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2024 | 1159 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1232 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2020 | 1909 | 0.100 |
Why?
|
| Nose Neoplasms | 2 | 2011 | 31 | 0.100 |
Why?
|
| Sporothrix | 1 | 2011 | 1 | 0.100 |
Why?
|
| Itraconazole | 1 | 2011 | 24 | 0.090 |
Why?
|
| Cats | 1 | 2011 | 116 | 0.090 |
Why?
|
| Aminoquinolines | 1 | 2008 | 35 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2011 | 290 | 0.080 |
Why?
|
| Mohs Surgery | 1 | 2008 | 42 | 0.070 |
Why?
|
| Male | 6 | 2020 | 60086 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12118 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 481 | 0.070 |
Why?
|
| Prognosis | 1 | 2015 | 4513 | 0.060 |
Why?
|
| Adult | 2 | 2016 | 29012 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1660 | 0.060 |
Why?
|
| Melanoma | 1 | 2011 | 824 | 0.060 |
Why?
|
| Cultural Diversity | 1 | 2024 | 63 | 0.060 |
Why?
|
| Child | 2 | 2015 | 24231 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8110 | 0.050 |
Why?
|
| Middle Aged | 3 | 2019 | 25989 | 0.050 |
Why?
|
| Cataract Extraction | 1 | 2020 | 210 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 604 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3665 | 0.030 |
Why?
|
| Keratins | 1 | 2011 | 55 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2011 | 45 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5047 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 33793 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 6369 | 0.020 |
Why?
|
| Ointments | 1 | 2008 | 14 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2008 | 143 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1237 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1590 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2307 | 0.010 |
Why?
|